Quad tendon for Anterior Cruciate Ligament Tear

Phase-Based Progress Estimates
UAB Hospital Highlands, Birmingham, AL
Anterior Cruciate Ligament Tear+2 More
BTB - Procedure
< 65
All Sexes
What conditions do you have?

Study Summary

The choice of autograft for ACL reconstruction continues to be debated. To date, there has only be one completed randomized controlled trial with quad tendon to BTB and the tendon included a bone plug. There has been no study to date comparing an all soft tissue quad tendon to patellar tendon in a randomized controlled trial for ACL reconstruction.

Eligible Conditions

  • Anterior Cruciate Ligament Tear
  • Orthopedic Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Anterior Cruciate Ligament Tear

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 2 years

2 years
Re-rupture rate
24 months
International Knee Documentation Committee (IKDC) Knee Evaluation Form
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Marx Activity Scale
Single Assessment Numeric Evaluation (SANE)
Visual analog scale (VAS)

Trial Safety

Safety Progress

1 of 3

Other trials for Anterior Cruciate Ligament Tear

Trial Design

2 Treatment Groups

Quad tendon
1 of 2
BTB tendon
1 of 2
Active Control

100 Total Participants · 2 Treatment Groups

Primary Treatment: Quad tendon · No Placebo Group · N/A

Quad tendon
ActiveComparator Group · 1 Intervention: Quad tendon · Intervention Types: Procedure
BTB tendon
ActiveComparator Group · 1 Intervention: BTB · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Trial Background

Prof. Amit Momaya, Associate Professor
Principal Investigator
University of Alabama at Birmingham
Closest Location: UAB Hospital Highlands · Birmingham, AL
Photo of Birmingham  1Photo of Birmingham  2Photo of Birmingham  3
2022First Recorded Clinical Trial
0 TrialsResearching Anterior Cruciate Ligament Tear
2 CompletedClinical Trials

Eligibility Criteria

Age < 65 · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are under 40 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.